Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity.
Odd L GammelgaardMikkel G TerpChristian RennAran F LabrijnOliver HamakerAaraby Yoheswaran NielsenHenriette VeverSoren Wk HansenMorten Frier GjerstorffChrista Elisabeth MüllerPaul W H I ParrenHenrik Jørn DitzelPublished in: Journal for immunotherapy of cancer (2022)
Our data collectively demonstrate that complementary anticancer mechanisms of action of distinct anti-CD73 Abs can be combined and enhanced in a biparatopic bsAb. The multiple mechanisms of action and superior activity compared with the monospecific parental Abs make the bsAb a promising candidate for therapeutic targeting of CD73 in cancer. This concept may greatly improve future Ab design.